Community-living nonagenarians in Northern Ireland have lower plasma homocysteine but similar methylenetetrahydrofolate reductase thermolabile genotype prevalence compared to 70-89-year-old subjects

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 207-214

  Rea, I M ^a   McMaster, D ^a   Woodside, J V ^a,b   Young, I S ^a   Archbold, G P R ^c   Linton, T ^c   Lennox, S ^a   McNulty, H ^d   Harmon, D L ^e   Whitehead, A S ^f  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ULSTER   (United Kingdom)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f NONE

Author keywords

Aging; B Vitamins; GFR; Homocysteine; MTHFR; Nonagenarian

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AGED; AGING; AMINO ACID BLOOD LEVEL; ARTICLE; COMMUNITY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; UNITED KINGDOM;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION; GENOTYPE; GLOMERULAR FILTRATION RATE; HEALTH STATUS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; NORTHERN IRELAND; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POPULATION SURVEILLANCE; PREVALENCE; VITAMIN B COMPLEX;

EID: 0033993437     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00417-7     Document Type: Article

References (48)

1. Stabler S.P. Screening the older population for Cobalamin (Vitamin B12) deficiency. J. Am. Ger. Soc. 43:1995;1290-1297.
2. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56:1969;111-128.
3. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease; probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1995;1049-1057.
4. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action project. J. Am. Med. Assoc. 277:1997;1775-1781.
5. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-236.
6. Perry I.J., Refsum H., Morris R.W., Ebrahim S., Ueland P.M., Shaper A.G. Prospective study of serum homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
7. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B. et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149-1155.
8. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:1995;704-709.
9. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D. et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J. Am. Med. Assoc. 268:1992;877-881.
10. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
11. Kang S.S., Wong P.W.K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 48:1991;536-545.
12. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
13. Harmon D.L., Woodside J.V., Yarnell J.W.G., McMaster D., Young I.S., McCrum E.E. et al. The common thermolabile variant of methylenetetrahydrofolatereductase is a major determinant of mild hyperhomocysteinaemia. Evidence for a common gene mutation. Q. J. Med. 89:1996;571-577.
14. Wilcken D.E.L. MTFHR 677C-T mutation, folate intake, neural tube defect and risk of cardiovascular disease. Lancet. 350:1997;603-604.
15. Brattstrom L., Wilcken D.E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the results of a meta-analysis. Circulation. 98:1998;2520-2526.
16. Ligthart G.L., Corberand J.X., Fournier C., Galanaud P., Hijmans W., Kennes B. et al. Admission criteria for immunogerontological studies in man: the 'Senieur' protocol. Mech. Ageing. Dev. 28:1984;47-55.
17. Harmon D.L., McMaster D., Shields D.C., Whitehead A.S., Rea I.M. MTHFR thermolabile genotype frequencies and longevity in Northern Ireland. Atherosclerosis. 131:1997;137-138.
18. Brattstrom L., Zhang Y., Hurtig M., Refsum H., Ostensson S., Fransson L. et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis. 141:1998;315-319.
19. Matsushita S., Muramatsu T., Arai H., Matsui T., Higuchi S. The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population. Am. J. Hum. Genet. 61:1997;1459-1460.
20. Faure-Delanef L., Quere I., Chasse J.F., Guerassimenko O., Lesaulnier M., Bellet H. et al. Methylenetetrahydrofolate reductase thermolabile variant and human longevity. Am. J. Hum. Genet. 60:1997;999-1001.
21. Selhub J., Jacques P.F., Wilson P.W.F., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J. Am. Med. Assoc. 270:1993;2693-2698.
22. Brattstrom L., Lindgren A., Israelsson B., Andersson A., Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle aged and elderly subjects. J. Int. Med. 236:1994;633-641.
23. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E. et al. Total plasma homocysteine and cardiovascular risk profile. J. Am. Med. Assoc. 274:1995;1526-1533.
24. Bates C.J., Mansoor M.A., van der Pols J., Prentice A., Cole T.J., Finch S. Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur. J. Clin. Nutr. 51:1997;691-697.
25. Silberberg J.S., Crook R., Fryer J.L., Nair B., Fletcher P.J., Guor X.W. et al. Are high homocytsteine levels a benign phenomenon in the elderly. Neth. J. Med. 52:1988;S12.
26. Rea I.M., Stewart M., Campbell P., Alexander H.D., Crockard A.D., Morris T.C.M. Changes in lymphocyte subsets, Interleukin 2 and soluble Interleukin 2 receptor in old and very old age. Gerontology. 42:1996;69-78.
27. The Northern Ireland Census 1991, Registrar General (Northern Ireland). HMSO 1992.
28. Folstein M.F., Folstein S.E., McHugh P.R. Mini mental state, a practical method for grading the cognitive state of patients for the clinician. J. Pyschiatr. Res. 12:1975;189-198.
29. Ubbink J.B., Vermaak W.J.H., Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J. Chromatogr. 565:1991;441-446.
30. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
31. Rea I.M., Gillen S., Clarke E. Anthropometric measurements from a cross-sectional survey of community living subjects aged >90 years of age. Eur. J. Clin. Nutr. 51:1997;102-106.
32. Fogt E.J., Bell S.J., Blackburn G.L. Nutritional assessment of the elderly. Morley J.E., Glick Z., Rubenstein L.Z. Geriatric Nutrition. A Comprehensive Review. 1995;1995 Raven Press, New York.
33. Woodside J., Yarnell J.W.G., McMaster D., Young I.S., Harmon D.L., McCrum E.E. et al. The effect of B vitamins and antioxidant vitamins on hyperhomocysteimemia: a double blind, randomised factorial-design controlled trial. Am. J. Clin. Nutr. 67:1998;858-866.
34. Gallagher P.M., Meleady R., Shields D.C., Soon Tan K., McMaster D., Rozen R., Evans A. et al. Homocysteine and risk of premature coronary heart disease. Circulation. 94:1996;2154-2158.
35. Dietary Reference Values of Food Energy and Nutrients for the United Kingdom, Department of Health, Report on Health and Social subjects. HMSO: London, 1991.
36. Rea IM, Nelson SJ, Murphy A, Ward M, McNulty H. Dietary assessment of nutritional status of 85-96 year old community-living subjects. In: Nutrition personnes agees. CERIN Symposium. Paris, 1997. p. 333.
37. Mudd S.H., Poole J.R. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 24:1975;721-735.
38. Clarke R. Homocysteine lowering trialist's collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J. 316:1998;894-898.
39. Naurath H.J., Joosten E., Riezler R., Stabler S.P., Allen R.H., Lindenbaum J. Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 346:1995;85-89.
40. Brattstrom L. Vitamins as homocysteine-lowering agents. J. Nutr. 126:1996;1276S-1280S.
41. Pennypacker L.C., Allen R.H., Kelly J.P., Matthews L.M., Grigsby J., Kaye K. et al. High prevalence of Cobalamin deficiency in elderly outpatients. J. Am. Ger. Soc. 40:1992;1197-1204.
42. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J. et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
43. Robinson K., Gupta A., Dennis V., Arheart K., Chaudhary D., Green R. et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 94:1996;2743-2748.
44. Nygard O., Refsum H., Ueland P.M., Vollset S.E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland homocysteine study. Am. J. Clin. Nutr. 67:1998;263-270.
45. Nygard O., Refsum H., Ueland P.M., Stensvold I., Nordrehaug J.E., Kvale G. et al. Coffee consumption and plasma total homocysteine: the Hordaland homocysteine study. Am. J. Clin. Nutr. 65:1997;136-143.
46. Guttormsen A.B., Schneede J., Ueland P.M., Refsum H. Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am. J. Clin. Nutr. 63:1996;194-202.
47. Freidman G., Ben-Yehuda A., Dabach Y., Ben-Naim M., Hollander G., Retter O. et al. Scavenger receptor activity and expression of apolipoprotein E mRNA in monocyte-derived macrophages of young and healthy men. Atherosclerosis. 128:1997;67-73.
48. Wauquier A., van Sweden B., Lagaay A.M., Kemp B., Kamohuisen H.A. Ambulatory monitoring of sleep-wakefulness patterns in healthy elderly males and females (greater than 88 years): the 'Senieur' protocol. J. Am. Ger. Soc. 40:1992;108-114.